HSD17B10 and early-onset autosomal dominant Alzheimer disease: Clarification of the alleged differences between 17β-HSD10 and ABAD will go far in helping to restore a proper understanding in the field as well as addressing research integrity issues in this field, which is essential for blazing an accurate and reliable path forward in the search for effective therapeutic targets for HSD17B10-gene-related disorders, including HSD10 deficiency or infantile neurodegeneration [36] and Alzheimer’s disease [7].